Literature DB >> 32977894

Quality of life of children and families.

Klajdi Puka1, Lauryn Conway2, Mary Lou Smith3.   

Abstract

Quality of life (QOL) is recognized as a key outcome of chronic health conditions and is increasingly used and recommended for clinical care and clinical trials. Neurocognitive developmental disorders and disabilities (NDD) are characterized by impairments or comorbidities in multiple areas of function, and, unsurprisingly, youth with NDD and their families have poorer QOL relative to their peers. The impact of NDD goes beyond the characteristic symptoms of the illness, and youth with NDD face numerous comorbidities and psychosocial problems that may have a large impact on QOL. In this chapter, first, we discuss the varying approaches and methodological considerations associated with the measurement of QOL and the implications of using "generic," "disease-specific," and proxy-reported measures of QOL. Second, we review the literature evaluating the QOL of youth with various NDD relative to healthy controls and factors associated with outcomes. Last, we conclude with a review of the literature outlining the importance of family environment, the compromised QOL of parents of youth with NDD, and the needs of parents. Evaluation of QOL is an important and recommended component of comprehensive care and clinical trials.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Attention deficit hyperactivity disorder; Autism spectrum disorder; Developmental coordination disorder; Epilepsy; Family environment; Intellectual disability; Parent; Psychosocial; Quality of life; Youth

Mesh:

Year:  2020        PMID: 32977894     DOI: 10.1016/B978-0-444-64148-9.00028-4

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  1 in total

1.  Non-disease specific patient-reported outcome measures of health-related quality of life in juvenile idiopathic arthritis: a systematic review of current research and practice.

Authors:  Justyna Młyńczyk; Paweł Abramowicz; Maciej K Stawicki; Jerzy Konstantynowicz
Journal:  Rheumatol Int       Date:  2021-12-31       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.